Review Article

Gastric Carcinogenesis and Underlying Molecular Mechanisms: *Helicobacter pylori* and Novel Targeted Therapy

Toshihiro Nishizawa^{1,2} and Hidekazu Suzuki¹

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

² Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

Correspondence should be addressed to Hidekazu Suzuki; hsuzuki1201@gmail.com

Received 14 August 2014; Accepted 15 October 2014

Academic Editor: Shigeru Kamiya

Copyright © 2015 T. Nishizawa and H. Suzuki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The oxygen-derived free radicals that are released from activated neutrophils are one of the cytotoxic factors of *Helicobacter pylori*-induced gastric mucosal injury. Increased cytidine deaminase activity in *H. pylori*-infected gastric tissues promotes the accumulation of various mutations and might promote gastric carcinogenesis. Cytotoxin-associated gene A (CagA) is delivered into gastric epithelial cells via bacterial type IV secretion system, and it causes inflammation and activation of oncogenic pathways. *H. pylori* infection induces epigenetic transformations, such as aberrant promoter methylation in tumor-suppressor genes. Aberrant expression of microRNAs is also reportedly linked to gastric tumorigenesis. Moreover, recent advances in molecular targeting therapies provided a new interesting weapon to treat advanced gastric cancer through anti-human epidermal growth factor receptor 2 (HER-2) therapies. This updated review article highlights possible mechanisms of gastric carcinogenesis including *H. pylori*-associated factors.

1. Introduction

Helicobacter pylori infection is one of the most prevalent infectious diseases worldwide and 40–50% of the global human population is estimated to be infected. *H. pylori* has been identified as a group 1 carcinogen by the World Health Organization International Agency for Research on Cancer (WHO/IARC, 69372 Lyon CEDEX 08, France) and is associated with the development of noncardia gastric cancer. Eradication of *H. pylori* infection has been reported as an effective strategy for both the treatment of peptic ulcers and gastric mucosa-associated lymphoid tissue (MALT) lymphoma as well as prevention of gastric cancer [1–3].

A randomized controlled trial (RCT) in Japan demonstrated significant prophylactic effects of *H. pylori* eradication on the development of metachronous gastric carcinoma after endoscopic resection [1]. According to a systemic review of 15 papers, *H. pylori* eradication significantly reduces the prevalence of gastric cancer by approximately one-third [4]. A recent meta-analysis of RCTs also shows that *H. pylori*

eradication seems to reduce gastric cancer risk [relative risk (RR): 0.65, 95% confidence interval (CI): 0.43–0.98] [5]. In 2009, the committee of the Japanese Society for Helicobacter Research (JSRH) revised the guidelines for diagnosis and treatment of *H. pylori* infection [6]. *H. pylori* eradication therapy achieved a strong recommendation, because it is useful for the treatment of gastric or duodenal ulcers, treatment and prevention of *H. pylori*-associated diseases such as gastric cancer, and inhibition of the spread of *H. pylori* infection.

Bacterial virulence factors, such as, cytotoxin-associated gene A (CagA), cause inflammation and activate oncogenic pathways. Activated neutrophils are the main source of reactive oxygen species (ROS) and reactive nitrogen species production in *H. pylori*-infected stomachs. Excessive oxidative stress can damage DNA in gastric epithelial cells, indicating its possible involvement in gastric carcinogenesis [7]. Gastric cancer arises from multiple genetic and epigenetic alterations in oncogenes, tumor-suppressor genes, cell cycle regulators, cell-adhesion molecules, and DNA repair genes.

Recent studies provided evidence that expression of an aberrant DNA/RNA editing enzyme, activation-induced cytidine deaminase (AID), might be a mechanism of mutation accumulation in the gastric mucosa during *H. pylori*-associated gastric carcinogenesis. The roles of microRNAs are increasingly apparent, and aberrant expression of microRNAs may contribute to the development and progression of gastric cancer. Moreover, recent advances in molecular therapies provided a new interesting weapon to treat advanced gastric cancer through anti-human epidermal growth factor receptor 2 (HER-2) therapies.

Consequently, this paper summarizes the molecular mechanism of *H. pylori*-associated gastric carcinogenesis.

2. Oxidative Stress

Oxygen-derived free radicals that are released from activated neutrophils are considered potential toxic factors that contribute to *H. pylori*-induced gastric mucosal injury. Neutrophils express myeloperoxidase, which produces the hypochlorous anion (OCl^-). OCl^- reacts with the ammonia (NH_3), which is produced from urea by *H. pylori*-associated urease, to yield a lipophilic, highly cytotoxic oxidant, monochloramine (NH_2Cl), that freely penetrates biological membranes to oxidize intracellular components [8]. Free radicals, including ROS and reactive nitrogen species, can bind with nucleic acids, turning them into mutated forms that play a role in multistep carcinogenesis [9].

The CD44 variant (CD44v), which is a cell-surface marker, that is associated with cancer stem-like cells, interacts with a glutamate-cystine transporter and controls the intracellular level of reduced glutathione (GSH) [10]. Human gastrointestinal cancer cells with a high level of CD44 expression revealed an enhanced capacity for glutathione synthesis and defense against ROS. These findings indicate that cancer stem-like cells with CD44v expression could have an ROS defense system that results from glutathione synthesis.

H. pylori upregulates spermine oxidase (SMOX) in gastric epithelial cells. SMOX metabolizes the polyamine spermine into spermidine and generates H_2O_2 , which causes apoptosis and DNA damage. However, a subpopulation of SMOX^{high} cells is resistant to apoptosis, despite their high levels of DNA damage. Chaturvedi et al. reported that activation of epidermal growth factor receptor (EGFR) and erythroblastic leukemia-associated viral oncogene B (ErbB2) by *H. pylori* results in survival of gastric epithelial cells with DNA damage [11].

3. CagA

Epidemiological evidence indicates that *H. pylori* strains containing CagA are more virulent. CagA-positive *H. pylori* increases the risk of both intestinal and diffuse types of noncardia gastric cancer [12]. The CagA protein of *H. pylori*, which is delivered into gastric epithelial cells via bacterial type IV secretion system, is an oncoprotein that can induce malignant neoplasms. After the CagA protein is injected into the host cell cytoplasm, the EPIYA (Glu-Pro-Ile-Tyr-Ala)

motif of CagA is tyrosine-phosphorylated by host Src kinases and subsequently changes the gastric epithelial morphology [13]. CagA binding to the protooncogene Src homology 2-containing protein tyrosine phosphatase (SHP-2) causes aberrant activation of SHP-2 and consequently of the ERK-MAPK (mitogen-activated protein kinase) pathway, which has been reported to play a role in carcinogenesis by inducing mitogenic responses [14]. East Asian CagA that contains the EPIYA-D motif demonstrates higher affinity for SHP-2 than Western CagA. These findings are consistent with the fact that East Asian strains dominate in countries with the highest rates of gastric cancer [15].

On the other hand, CagA interacts with many signaling molecules (e.g., Per-1, c-Abl, Crk proteins, Grb proteins, and c-Met) that are important for the regulation of cell proliferation, scattering, and morphology (Figure 1). CagA, that is translocated into the host cell, is degraded by autophagy and short-lived. However, CagA, that is translocated into CD44v9-positive gastric cancer stem-like cells, which are characterized by ROS resistance that results from their rich GSH content, is thought to escape ROS-dependent autophagy, resulting in gastric carcinogenesis [16].

4. AID

The DNA/RNA editing enzyme, AID, is a 198 amino acid protein that directly converts cytosine into uracil (Figure 2). AID is specifically induced in germinal center B cells to carry out somatic hypermutation and class-switch recombination, which are two processes that are responsible for antibody diversification. Because of its mutagenic potential, AID expression and activity are tightly regulated to minimize unwanted DNA damage. Surprisingly, AID is also induced by inflammation and microbial infections in nonimmune cells.

H. pylori infection mediates aberrant AID expression in gastric mucosal epithelial cells. Additionally, AID expression was shown to be triggered by proinflammatory cytokines, such as $\text{TNF-}\alpha$ or IL-1, and correlated with mononuclear cell infiltration and intestinal metaplasia. After eradication of *H. pylori*, the level of AID expression decreases [17]. Strong evidence indicates that CagA-positive *H. pylori*-mediated upregulation of AID resulted in the accumulation of nucleotide alterations in the TP53 tumor suppressor gene in gastric cells [18]. Whole-exome sequencing revealed that somatic mutations accumulated in various genes in inflamed gastric tissues. The mutations that accumulated in gastric tumors as well as gastric mucosal tissues with *H. pylori*-induced gastritis were predominantly C : G > T : A transitions in GpCpX motifs, which are markers of cytidine deamination that are induced by AID [19]. Increased cytidine deaminase activity in *H. pylori*-infected gastric tissues appears to promote the accumulation of various mutations and might promote gastric carcinogenesis.

5. Oncogenes

Mutational activation and/or amplification of several oncogenes such as ErbB, KRAS, PIK3CA, MET, and MYC has been documented in gastric cancer.

FIGURE 1: CagA and major functions. CagA is delivered into gastric epithelial cells via bacterial type IV secretion system. CagA interacts with many signaling molecules that are important for the regulation of cell proliferation, polarity, and motility.

FIGURE 2: Activation-induced cytidine deaminase (AID) as the DNA/RNA editing enzyme. AID is induced by *H. pylori* infection and promotes the accumulation of various mutations.

Epidermal growth factor receptor (EGFR), a member of ErbB receptor family, is involved in the regulation of gastric mucosal cell proliferation and progression of gastric cancer. Overexpression of ErbB1 (EGFR) and ErbB2 (HER-2) is found in 27–64% and 6–34% of gastric cancer, respectively [20]. Activation triggers a cascade of events that involves autophosphorylation and activation of tyrosine kinase domain, Ras/Raf/MAPK pathway, phospholipase C- γ , and phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR). Ras, an oncogenic small GTPase, has three isoforms, namely, K-Ras, H-ras, and N-ras. Constitutive activation of Ras and Ras-related proteins promotes cell proliferation and increase invasion and metastasis while inhibiting apoptotic cell death. *K-RAS* gene was found to be mutated (codon-12) in intestinal-type cancer, but not in diffuse-type cancer [21]. *K-RAS* gene mutations in *H. pylori*-associated chronic gastritis are more frequent in gastric cancer patients than in cancer-free patients, suggesting that *K-RAS* mutation may be involved in the early stage of gastric carcinogenesis [22].

Trastuzumab is a monoclonal antibody that binds to extracellular domain of the receptor, acting by blockage of the HER-2 receptor cleavage, inhibition of dimerization, and the induction of antibody-dependent cellular cytotoxicity (ADCC). In phase III ToGA trial, the addition of trastuzumab to standard cisplatin and 5-fluorouracil improved overall

survival from 11.1 to 13.8 months in patients with HER-2 amplified gastric adenocarcinomas [23]. In phase III EXPAND trial, the addition of cetuximab (chimeric monoclonal anti-EGFR antibody) to standard cisplatin and capecitabine did not improve progression free survival in patients with advanced gastric cancer [24]. Similarly, in phase III REAL-3 trial, the addition of panitumumab (fully humanized monoclonal anti-EGFR antibody) to epirubicin, oxaliplatin, and capecitabine did not improve overall survival in patients with advanced gastric adenocarcinoma [25]. In addition, retrospective biomarker analysis has failed to identify a clear patient subset that would derive benefit from EGFR-directed therapies. Lapatinib is dual tyrosine kinase inhibitor active on EGFR and HER-2. In phase III TYTAN trial, the addition of lapatinib to weekly paclitaxel in second-line setting improved overall response rate in patients with HER-2-positive gastric adenocarcinomas (odds ratio, 3.85; 95% CI, 1.80–8.87, $P < 0.001$) but did not significantly improve overall survival (lapatinib+paclitaxel, 11.0 versus paclitaxel, 8.9 months; $P = 0.104$) [26].

Phase III GRANITE-1 study evaluated the efficacy of mTOR inhibitor everolimus compared to the best supportive care in patients with advanced gastric cancer that progressed after initial chemotherapy. In this study, median survival was reportedly 5.39 months with everolimus versus 4.34 months with placebo (HR = 0.90; 95% CI, 0.75–1.08) [27]. Patients in this study were not preselected with respect to PI3K/AKT/mTOR pathway alteration.

6. Tumor-Suppressor Genes

The *p53* tumor-suppressor gene, the guardian of human genome, is frequently inactivated in the tissue of gastric cancer as well as in preneoplastic lesions, by loss of heterozygosity (LOH), missense mutation, or frame-shift deletions [12]. The *p53*, 53 kDa phosphoprotein, is a transcription factor for including DNA repair genes in response to DNA damage. Activation of *p53* also arrests the cell cycle to allow enough time for fixation of DNA damage. However, if DNA damage is beyond repair, *p53* induces apoptotic cell death. The mutations of *p53* have also been identified in gastric adenoma and intestinal metaplasia. We have recently reported that *p53* downregulation due to increased MDM2-phosphorylation induces autophagy, which causes CagA oncoprotein degradation translocated from the bacterial body of *H. pylori* to gastric epithelial cells and then inhibits mTOR [16].

APC is a multidomain protein with binding sites for numerous proteins including Wnt signaling pathway. APC plays major role in cell adhesion, cell migration, spindle formation, and chromosome segregation [28]. APC mutations are the second most frequent mutations in gastric cancer and have been observed in 30–40% of intestinal type cancer and in less than 2% of diffuse type cancer [29]. The mutations of APC have also been identified in gastric adenoma and intestinal metaplasia, indicating that they occur during preneoplastic stage of gastric cancer development. LOH and mutations of phosphatase and tensin homolog (*PTEN*) were observed in gastric cancers as well as in precancerous lesions [30].

7. DNA Methylation

Methylation of CpG islands in a promoter region inhibits gene transcription by interfering with transcriptional initiation and serves as an alternative mechanism of inactivating tumor suppressor genes without gene mutation. Among factors known to cause aberrant DNA methylation, aging and chronic inflammation are known to promote the accumulation of DNA methylation. *H. pylori* infection induces aberrant promoter methylation in tumor-suppressor genes, including *p16*, *LOX*, and *CDH1*. Furthermore, a number of tumor suppressor genes, including *hMLM1*, *p14*, *p15*, *GSTP1*, *RASSF1*, *COX-2*, *APC*, *CDH4*, *DAP-K*, *THBS1*, *TIMP-3*, *RAR β* , *MGMT*, *CHFR*, *DCC*, *RUNX3*, and *TSLC1*, are known to be silenced by hypermethylation in gastric cancer [31] (Figure 3).

Recent meta-analysis revealed that the frequencies of *p16* promoter methylation in gastric cancer tissue were higher than those of normal and adjacent tissues [Normal: odds ratio (OR) = 23.04, 95% CI = 13.55–39.15, $P < 0.001$; Adjacent: OR = 4.42, 95% CI = 1.66–11.76, $P = 0.003$]. Furthermore, significant associations of *p16* promoter methylation with TNM stage, histologic grade, invasive grade, and lymph node metastasis are shown (TNM stage: OR = 3.60, 95% CI: 2.17–5.98, $P < 0.001$; Histologic grade: OR = 2.63, 95% CI: 1.55–4.45, $P < 0.001$; Invasive grade: OR = 3.44, 95% CI: 1.68–7.06, $P = 0.001$; Lymph node metastasis: OR = 2.68, 95% CI: 1.66–4.32, $P < 0.001$) [32].

Forkhead box (Fox) proteins comprise an evolutionarily conserved family of transcriptional regulators. In particular, FOXD3 bound directly to the promoters and activated transcription of genes that encode the cell death regulators CYFIP2 and RARB. Recent methylation profile analyses revealed that FOXD3-mediated transcriptional control of tumor suppressors is deregulated by *H. pylori* infection-induced hypermethylation [33]. Alternatively, CagA enhanced DNA methyltransferase 3B and enhancer of zeste homologue 2 expression, which resulted in the attenuation of *let-7* expression by histone and DNA methylation [34]. Aberrant epigenetic silencing of *let-7* expression leads to Ras upregulation.

DNA methylation levels of specific CpG islands are associated with risk of gastric cancer. Nanjo et al. identified seven novel gastric cancer risk markers that reflect epigenomic damage, that is induced by *H. pylori* infection, and the hypermethylated CpG islands had high ORs (12.7–36.0) in an analysis [35]. Moreover, 5-aza-2'-deoxycytidine (5-aza-dC) is a DNA demethylating agent. Niwa et al. showed that 5-aza-dC treatment can prevent *H. pylori*-induced gastric cancers in the Mongolian gerbil model [36]. Removal of induced DNA methylation and/or suppression of DNA methylation induction could become a target for prevention of chronic inflammation-associated cancers.

8. Angiogenesis

Elevated concentrations of vascular endothelial growth factor (VEGF) have been described in patients with advanced gastric cancer and correlated with decreased survival. VEGF

FIGURE 3: DNA methylation inactivates tumor suppressor genes without gene mutation. Chronic inflammation by *H. pylori* infection induces aberrant promoter methylation in tumor-suppressor genes.

and VEGF receptors are overexpressed in 36–40% of gastric cancer. Phase III AVAGAST and AVATAR studies have evaluated the addition of bevacizumab (anti-VEGF-A monoclonal antibody) to first-line platinum-fluoropyrimidine chemotherapy in advanced gastric cancer patients but failed to demonstrate improved survival [37, 38].

Phase III REGARD trial evaluated the efficacy of ramucirumab, a monoclonal antibody VEGFR-2 antagonist, compared to the best supportive care (BSC) in patients with advanced gastric cancer that progressed after previous chemotherapy. Median survival was 5.2 months with ramucirumab versus 3.8 months with placebo (HR = 0.776; 95% CI 0.603–0.998; $P = 0.047$) [39]. Based on data from this REGARD trial, the Food and Drug Administration (FDA) in United States approved ramucirumab as second-line therapy for patients with advanced gastric cancer.

Apatinib, inhibitor of VEGF-2, showed improved progression free survival and overall survival in heavily pretreated patients with metastatic gastric cancer in phase II trial [40]. Phase III trial of apatinib is ongoing.

9. MicroRNAs

MicroRNAs are noncoding RNAs that are comprised of 18–24 nucleotides that can posttranscriptionally downregulate various target genes. Recent studies have shown that a considerable number of microRNAs are altered following infection with *H. pylori*, and specific microRNA deregulation was found to contribute to host inflammation, cell-cycle progression, inhibition of apoptosis, cell invasion, and metastasis [41]. MicroRNAs that function as oncogenes, including *miR-17*, *miR-21*, and *miR-106a*, were upregulated, whereas microRNAs that function as tumor suppressors, such as *miR-101*, *miR-181*, *miR-449*, *miR-486*, and *let-7a*, were downregulated in gastric cancer [42, 43].

Shiotani et al. reported that the expression of oncogenic microRNAs (*miR-17/92* and the *miR-106b-93-25* cluster, *miR-21*, *miR-194*, and *miR-196*) is significantly higher in the intestinal than nonintestinal metaplasia. *H. pylori* eradication improves microRNA deregulation, but not in the intestinal metaplasia. MicroRNA deregulation is not completely reversible by eradication alone in long-term *H. pylori* colonization [44].

Runt domain transcription factor 3 (RUNX3) is a tumor suppressor, that is silenced in cancer via hypermethylation of its promoter. Previously, we reported that *H. pylori* eradication significantly increases RUNX3 expression in gastric epithelial cells [45]. Lai et al. reported that *miR-130b* expression is upregulated in gastric cancer, and this is inversely associated with *Runx3* hypermethylation [46]. *miR-130b* overexpression increases cell viability and reduces cell death following the downregulation of RUNX3 protein expression. Recently, Wang et al. reported that *miR-301a* is upregulated in gastric cancer and directly downregulates RUNX3 expression [47].

Furthermore, *microR-34b/c* is considered a tumor suppressor and transcriptional target of p53. Based on a scheduled follow-up study of endoscopic biopsy from noncancerous mucosa in the gastric body from 129 patients after curative endoscopic resection of gastric cancer, the cumulative incidence of metachronous gastric cancer was significantly higher among patients with elevated *miR-34b/c* methylation, indicating that methylation of *miR-34b/c* in the gastric mucosa may be a useful biomarker for predicting the risk of metachronous gastric cancer [48].

10. Cancer Stem Cell

Cancer stem cells have been defined as a unique subpopulation in tumors that possess the ability to initiate tumor growth and sustain tumor self-renewal. Gastric cancer stem cells were first isolated and identified in 2009. Takaishi et al. identified CD44 as a gastric cancer stem cell marker as CD44+ cells were able to form into spheroid colonies in serum-free media *in vitro* and gastric tumors after xenografts in nude mice *in vivo*, whereas CD44-negative sorted cells were not [49]. These cells have the ability for self-regeneration and resistance for chemotherapy- or radiation-induced cell death. Cancer stem cells-targeted therapy is a novel direction for treating and preventing gastric cancer. In our recent study, translocated CagA from *H. pylori* to the epithelial cells could accumulate in CD44v9-expressing gastric cancer stem-like cells by escaping the autophagic degradation pathway due to their characteristics of xCT-dependent ROS resistance [16].

The high expression of CD44 is positively correlated with malignant transformation, metastasis, and relapse of gastric cancer [50]. We previously reported that the recurrence rate of early gastric cancer was significantly higher in the CD44v9-positive than the CD44v9-negative cohorts (hazard ratio, 21.8; 95% CI, 5.71–83.1) [42]. CD44v9 expression in the tissue of primary gastric cancer represents a potential predictive marker for recurrence.

Additionally, there is another hypothesis. It is thought that gastric cancer stem cells are derived from bone-marrow-derived mesenchymal stem cells. When there is injury, the bone-marrow-derived mesenchymal stem cells can mobilize from the bone marrow and participate in tissue repair. Varon et al. labeled bone-marrow-derived cells with green fluorescent protein in mice model of infection with *H. pylori*. After 1 year, gastric glands that contained green fluorescent protein-positive cells were detected in 90% of mice infected with *H. pylori*. Almost 25% of high-grade dysplastic lesions included cells originating from the bone marrow [51]. The results suggest that bone-marrow-derived mesenchymal stem cells are the source of gastric cancer.

11. Conclusion

As shown in this review, molecular mechanisms of gastric carcinogenesis have been extensively studied. Alterations in multiple genes and complex copy number and gene expression profiles have been identified in gastric cancer over the two decades. New strategies had been developed for advanced gastric cancer treatment. However, the response rates remain in the 25–40% range across published trials, and novel molecularly directed approaches are needed.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

We would like to thank Drs. Takanori Kanai and Naohisa Yahagi for their comments to the final version of the paper.

References

- [1] K. Fukase, M. Kato, S. Kikuchi et al., "Effect of eradication of *Helicobacter pylori* on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial," *The Lancet*, vol. 372, no. 9636, pp. 392–397, 2008.
- [2] H. Suzuki, T. Nishizawa, and T. Hibi, "*Helicobacter pylori* eradication therapy," *Future Microbiology*, vol. 5, no. 4, pp. 639–648, 2010.
- [3] T. Nishizawa, H. Suzuki, I. Nakagawa et al., "Early *Helicobacter pylori* eradication restores sonic hedgehog expression in the gastric mucosa of mongolian gerbils," *Digestion*, vol. 79, no. 2, pp. 99–108, 2009.
- [4] M. Ito, S. Takata, M. Tatsugami et al., "Clinical prevention of gastric cancer by *Helicobacter pylori* eradication therapy: a systematic review," *Journal of Gastroenterology*, vol. 44, no. 5, pp. 365–371, 2009.
- [5] L. Fuccio, R. M. Zagari, L. H. Eusebi, L. Laterza, V. Cennamo, and L. Ceroni, "Meta-analysis: can *Helicobacter pylori* eradication treatment reduce the risk for gastric cancer?" *Annals of Internal Medicine*, vol. 151, no. 7, pp. 121–128, 2009.
- [6] M. Asaka, M. Kato, S.-I. Takahashi et al., "Guidelines for the management of *Helicobacter pylori* infection in Japan: 2009 revised edition," *Helicobacter*, vol. 15, no. 1, pp. 1–20, 2010.

- [7] H. Suzuki, T. Nishizawa, H. Tsugawa, and T. Hibi, "Molecular approaches and modern clinical strategies for the management of *Helicobacter pylori* infection in Japan," *Keio Journal of Medicine*, vol. 61, no. 4, pp. 109–119, 2012.
- [8] M. Suzuki, S. Miura, M. Suematsu et al., "*Helicobacter pylori*-associated ammonia production enhances neutrophil-dependent gastric mucosal cell injury," *The American Journal of Physiology: Gastrointestinal and Liver Physiology*, vol. 263, no. 5, pp. G719–G725, 1992.
- [9] H. Suzuki, T. Nishizawa, H. Tsugawa, S. Mogami, and T. Hibi, "Roles of oxidative stress in stomach disorders," *Journal of Clinical Biochemistry and Nutrition*, vol. 50, no. 1, pp. 35–39, 2012.
- [10] T. Ishimoto, O. Nagano, T. Yae et al., "CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc⁻ and thereby promotes tumor growth," *Cancer Cell*, vol. 19, no. 3, pp. 387–400, 2011.
- [11] R. Chaturvedi, M. Asim, M. B. Piazuelo et al., "Activation of EGFR and ERBB2 by *Helicobacter pylori* results in survival of gastric epithelial cells with DNA damage," *Gastroenterology*, vol. 146, no. 7, pp. 1739.e14–1751.e14, 2014.
- [12] S. Nagini, "Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention," *World Journal of Gastrointestinal Oncology*, vol. 4, no. 7, pp. 156–169, 2012.
- [13] M. Hatakeyama, "Oncogenic mechanisms of the *Helicobacter pylori* CagA protein," *Nature Reviews Cancer*, vol. 4, no. 9, pp. 688–694, 2004.
- [14] M. Hatakeyama, "*Helicobacter pylori* CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis," *Cell Host & Microbe*, vol. 15, pp. 306–316, 2014.
- [15] H. Higashi, R. Tsutsumi, A. Fujita et al., "Biological activity of the *Helicobacter pylori* virulence factor CagA is determined by variation in the tyrosine phosphorylation sites," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 22, pp. 14428–14433, 2002.
- [16] H. Tsugawa, H. Suzuki, H. Saya et al., "Reactive oxygen species-induced autophagic degradation of *Helicobacter pylori* CagA is specifically suppressed in cancer stem-like cells," *Cell Host and Microbe*, vol. 12, no. 6, pp. 764–777, 2012.
- [17] N. Nagata, J. Akiyama, H. Marusawa et al., "Enhanced expression of activation-induced cytidine deaminase in human gastric mucosa infected by *Helicobacter pylori* and its decrease following eradication," *Journal of Gastroenterology*, vol. 49, no. 3, pp. 427–435, 2014.
- [18] Y. Matsumoto, H. Marusawa, K. Kinoshita et al., "*Helicobacter pylori* infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium," *Nature Medicine*, vol. 13, no. 4, pp. 470–476, 2007.
- [19] T. Shimizu, H. Marusawa, Y. Matsumoto et al., "Accumulation of somatic mutations in TP53 in gastric epithelium with *Helicobacter pylori* infection," *Gastroenterology*, vol. 147, no. 2, pp. 407.e3–417.e3, 2014.
- [20] W. Yang, A. Raufi, and S. J. Klempner, "Targeted therapy for gastric cancer: molecular pathways and ongoing investigations," *Biochimica et Biophysica Acta*, vol. 1846, no. 1, pp. 232–237, 2014.
- [21] H.-C. Chen, H.-J. Chen, M. A. Khan et al., "Genetic mutations of p53 and k-ras in gastric carcinoma patients from Hunan, China," *Tumor Biology*, vol. 32, no. 2, pp. 367–373, 2011.
- [22] T. Hiyama, K. Haruma, Y. Kitadai et al., "K-ras mutation in *Helicobacter pylori*-associated chronic gastritis in patients with and without gastric cancer," *International Journal of Cancer*, vol. 97, no. 5, pp. 562–566, 2002.
- [23] Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al., "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial," *The Lancet*, vol. 376, no. 9742, pp. 687–697, 2010.
- [24] F. Lordick, Y.-K. Kang, H.-C. Chung et al., "Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial," *The Lancet Oncology*, vol. 14, no. 6, pp. 490–499, 2013.
- [25] T. Waddell, I. Chau, D. Cunningham et al., "Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial," *The Lancet Oncology*, vol. 14, no. 6, pp. 481–489, 2013.
- [26] T. Satoh, R. H. Xu, H. C. Chung et al., "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study," *Journal of Clinical Oncology*, vol. 32, pp. 2039–2049, 2014.
- [27] A. Ohtsu, J. A. Ajani, Y.-X. Bai et al., "Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study," *Journal of Clinical Oncology*, vol. 31, no. 31, pp. 3935–3943, 2013.
- [28] H. I. Grabsch and P. Tan, "Gastric cancer pathology and underlying molecular mechanisms," *Digestive Surgery*, vol. 30, no. 2, pp. 150–158, 2013.
- [29] A. Horii, S. Nakatsuru, Y. Miyoshi et al., "The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer," *Cancer Research*, vol. 52, no. 11, pp. 3231–3233, 1992.
- [30] Y.-G. Wen, Q. Wang, C.-Z. Zhou, G.-Q. Qiu, Z.-H. Peng, and H.-M. Tang, "Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway," *Oncology Reports*, vol. 24, no. 1, pp. 89–95, 2010.
- [31] X.-T. Hu and C. He, "Recent progress in the study of methylated tumor suppressor genes in gastric cancer," *Chinese Journal of Cancer*, vol. 32, no. 1, pp. 31–41, 2013.
- [32] H.-L. Wang, P.-Y. Zhou, P. Liu, and Y. Zhang, "Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis," *Molecular Biology Reports*, vol. 41, no. 7, pp. 4481–4492, 2014.
- [33] A. S. L. Cheng, M. S. Li, W. Kang et al., "*Helicobacter pylori* causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis," *Gastroenterology*, vol. 144, no. 1, pp. 122.e9–133.e9, 2013.
- [34] Y. Hayashi, M. Tsujii, J. Wang et al., "CagA mediates epigenetic regulation to attenuate let-7 expression in *Helicobacter pylori*-related carcinogenesis," *Gut*, vol. 62, no. 11, pp. 1536–1546, 2013.
- [35] S. Nanjo, K. Asada, S. Yamashita et al., "Identification of gastric cancer risk markers that are informative in individuals with past *H. pylori* infection," *Gastric Cancer*, vol. 15, no. 4, pp. 382–388, 2012.
- [36] T. Niwa, T. Toyoda, T. Tsukamoto, A. Mori, M. Tatematsu, and T. Ushijima, "Prevention of *Helicobacter pylori*-induced gastric cancers in gerbils by a DNA demethylating agent," *Cancer Prevention Research*, vol. 6, no. 4, pp. 263–270, 2013.
- [37] E. van Cutsem, S. de Haas, Y.-K. Kang et al., "Bevacizumab in combination with chemotherapy as first-line therapy in

- advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial,” *Journal of Clinical Oncology*, vol. 30, no. 17, pp. 2119–2127, 2012.
- [38] L. Shen, J. Li, J. Xu et al., “Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study),” *Gastric Cancer*, 2014.
- [39] C. S. Fuchs, J. Tomasek, C. J. Yong et al., “Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial,” *The Lancet*, vol. 383, no. 9911, pp. 31–39, 2014.
- [40] J. Li, S. Qin, J. Xu et al., “Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial,” *Journal of Clinical Oncology*, vol. 31, no. 26, pp. 3219–3225, 2013.
- [41] T. Nishizawa and H. Suzuki, “The role of microRNA in gastric malignancy,” *International Journal of Molecular Sciences*, vol. 14, no. 5, pp. 9487–9496, 2013.
- [42] K. Hirata, H. Suzuki, H. Imaeda et al., “CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence,” *British Journal of Cancer*, vol. 109, no. 2, pp. 379–386, 2013.
- [43] Y.-Y. Ma and H.-Q. Tao, “Microribonucleic acids and gastric cancer,” *Cancer Science*, vol. 103, no. 4, pp. 620–625, 2012.
- [44] A. Shiotani, N. Uedo, H. Iishi et al., “*H. pylori* eradication did not improve dysregulation of specific oncogenic miRNAs in intestinal metaplastic glands,” *Journal of Gastroenterology*, vol. 47, no. 9, pp. 988–998, 2012.
- [45] M. Suzuki, H. Suzuki, Y. Minegishi, K. Ito, T. Nishizawa, and T. Hibi, “*H. pylori*-eradication therapy increases RUNX3 expression in the glandular epithelial cells in enlarged-fold gastritis,” *Journal of Clinical Biochemistry and Nutrition*, vol. 46, no. 3, pp. 259–264, 2010.
- [46] K. W. Lai, K. X. Koh, M. Loh et al., “MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer,” *European Journal of Cancer*, vol. 46, no. 8, pp. 1456–1463, 2010.
- [47] M. Wang, C. Li, B. Yu et al., “Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer,” *Journal of Gastroenterology*, vol. 48, no. 9, pp. 1023–1033, 2013.
- [48] R. Suzuki, E. Yamamoto, M. Nojima et al., “Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk,” *Journal of Gastroenterology*, vol. 49, no. 7, pp. 1135–1144, 2014.
- [49] S. Takaishi, T. Okumura, S. Tu et al., “Identification of gastric cancer stem cells using the cell surface marker CD44,” *Stem Cells*, vol. 27, no. 5, pp. 1006–1020, 2009.
- [50] Y. Wakamatsu, N. Sakamoto, H. Z. Oo et al., “Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer,” *Pathology International*, vol. 62, no. 2, pp. 112–119, 2012.
- [51] C. Varon, P. Dubus, F. Mazurier et al., “*Helicobacter pylori* infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice,” *Gastroenterology*, vol. 142, no. 2, pp. 281–291, 2012.